Table 3.
Comparison of baseline and follow-up data of 29 patients with COVID-19
| Variables | Baseline | Follow-up | P-values |
|---|---|---|---|
| Gender, male, % | 15 (51.7%) | – | |
| Age, years | 43.9 ± 16.5 | – | |
| Severity | 10/12/5/2 | – | |
| Length of follow-up, days | – | 21.2 ± 7.0 | |
| Leukocyte, ×109/L | 6.24 ± 2.65 | 6.67 ± 2.22 | 0.28 |
| Lymphocyte, ×109/L | 1.37 ± 0.87 | 1.55 ± 0.58 | 0.33 |
| Platelet, ×109/L | 195.60 ± 77.75 | 198.67 ± 65.41 | 0.80 |
| Albumin, g/L | 42.24 ± 5.26 | 46.79 ± 2.86 | 6.0 × 10−6 |
| Lactose dehydrogenase, U/L | 232.31 ± 85.94 | 152.79 ± 71.17 | 5.2 × 10−5 |
| BNP, pg/mL | 31.70 (11.83–61.35) | 14.30 (0–55.15) | 0.002 |
| Proteinuriaa | 15/1/2 | – | |
| Hematuriaa | 11/5/2 | – | |
| Blood urea nitrogen, mmol/L | 3.82 ± 1.63 | 3.89 ± 1.42 | 0.66 |
| SCr, μmol/L | 61.92 ± 16.42 | 60.31 ± 14.36 | 0.83 |
Data are presented as number/total (percentage), mean ± SD or median (interquartile range). The severity categories included mild (10 cases), moderate (12 cases), severe (5 cases) and critical severe (2 cases).
a
The urinalysis categories included 0, 1+, 2+/3+. The length of follow-up was this counted from discharge of the patients.